Elevating Lymphatic Delivery in Immunology and Oncology
Sector
MedTech
Company
Emerging MedTech
Therapeutic Area
Oncology and Immunology
Treatment Modality
Drug-Device
Product Stage
Clinical
Expertise
Strategy
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver biologics directly into the lymphatic system. The technology promised to shift how immunology and oncology therapies are administered, offering improved bioavailability and targeted lymphatic delivery compared with conventional subcutaneous or intravenous approaches. For a small team competing for pharma attention, the challenge was not just to demonstrate the engineering, but to build a scientifically credible platform narrative that could stand alongside drug innovation programs.
Situation
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver biologics directly into the lymphatic system. The technology promised to shift how immunology and oncology therapies are administered, offering improved bioavailability and targeted lymphatic delivery compared with conventional subcutaneous or intravenous approaches. For a small team competing for pharma attention, the challenge was not just to demonstrate the engineering, but to build a scientifically credible platform narrative that could stand alongside drug innovation programs.
Situation
Approach
Our work focused on elevating the platform from a novel device concept to a pharma-grade therapeutic solution. We translated complex device engineering and lymphatic biology into clear, evidence-driven communications that resonated with both clinical experts and commercial decision-makers. This included building a scientific lexicon to explain the mechanism and value, developing narratives for congress presentations and scientific forums, and creating partnering materials that framed the platform as complementary to pharma pipelines rather than a niche device play. We also supported external communications to emphasize regulatory readiness and alignment with pharma-quality standards, ensuring it was viewed as credible and scalable.
Our work focused on elevating the platform from a novel device concept to a pharma-grade therapeutic solution. We translated complex device engineering and lymphatic biology into clear, evidence-driven communications that resonated with both clinical experts and commercial decision-makers. This included building a scientific lexicon to explain the mechanism and value, developing narratives for congress presentations and scientific forums, and creating partnering materials that framed the platform as complementary to pharma pipelines rather than a niche device play. We also supported external communications to emphasize regulatory readiness and alignment with pharma-quality standards, ensuring it was viewed as credible and scalable.
Approach
Results
By reframing the platform around rigorous science and therapeutic impact, the company was able to present itself as a serious partner to top pharma. The platform gained visibility at key congresses, strengthened engagement with KOLs in immunology and oncology, and positioned itself for licensing conversations with potential collaborators. What began as a device story became a differentiated narrative of a drug-device combination platform—opening the door to broader adoption and long-term integration into biopharma pipelines.
By reframing the platform around rigorous science and therapeutic impact, the company was able to present itself as a serious partner to top pharma. The platform gained visibility at key congresses, strengthened engagement with KOLs in immunology and oncology, and positioned itself for licensing conversations with potential collaborators. What began as a device story became a differentiated narrative of a drug-device combination platform—opening the door to broader adoption and long-term integration into biopharma pipelines.
Situation
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver biologics directly into the lymphatic system. The technology promised to shift how immunology and oncology therapies are administered, offering improved bioavailability and targeted lymphatic delivery compared with conventional subcutaneous or intravenous approaches. For a small team competing for pharma attention, the challenge was not just to demonstrate the engineering, but to build a scientifically credible platform narrative that could stand alongside drug innovation programs.
Approach
Our work focused on elevating the platform from a novel device concept to a pharma-grade therapeutic solution. We translated complex device engineering and lymphatic biology into clear, evidence-driven communications that resonated with both clinical experts and commercial decision-makers. This included building a scientific lexicon to explain the mechanism and value, developing narratives for congress presentations and scientific forums, and creating partnering materials that framed the platform as complementary to pharma pipelines rather than a niche device play. We also supported external communications to emphasize regulatory readiness and alignment with pharma-quality standards, ensuring it was viewed as credible and scalable.
Results
By reframing the platform around rigorous science and therapeutic impact, the company was able to present itself as a serious partner to top pharma. The platform gained visibility at key congresses, strengthened engagement with KOLs in immunology and oncology, and positioned itself for licensing conversations with potential collaborators. What began as a device story became a differentiated narrative of a drug-device combination platform—opening the door to broader adoption and long-term integration into biopharma pipelines.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.